Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398251 | 0.83 | UHRF1 (0.56) | NOS3NOS1NOS2UHRF1SLC6A2 | |
| SCHEMBL28198255 | 0.83 | UHRF1 (0.50) | NOS3NOS1NOS2UHRF1CYP1A2 | |
| SCHEMBL10330646 | 0.81 | UHRF1 (0.48) | NOS3NOS1NOS2UHRF1CYP1A2 | |
| SCHEMBL24506838 | 0.80 | NOS3 (0.67) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL8934141 | 0.80 | NOS3 (0.37) | NOS3NOS1NOS2UHRF1SLC6A2 | |
| SCHEMBL7117731 | 0.79 | NOS3 (0.48) | NOS3NOS1NOS2UHRF1SLC6A2 | |
| SCHEMBL7723010 | 0.79 | UHRF1 (0.42) | NOS3NOS1NOS2UHRF1SLC6A2 | |
| SCHEMBL25908641 | 0.78 | UHRF1 (0.45) | NOS3NOS1NOS2UHRF1CYP1A2 | |
| SCHEMBL29198060 | 0.77 | UHRF1 (0.41) | NOS3NOS1NOS2UHRF1GABRP | |
| SCHEMBL7120097 | 0.77 | NOS3 (0.63) | NOS3NOS1NOS2UHRF1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902858-B2 | Nonlinear optical dye, photorefractive material composition, photorefractive substrate and hologram recording medium | TOYO KOHAN CO., LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-1996032391-A1 | PROCESS FOR PREPARING AZAINDOLES WITH AN ACTIVATED COPPER CHROMITE CATALYST BY CATALYTIC DEHYDROCYCLISATION OF ALKYLPYRIDYLAMINES (PYRIDOPYRIDINES) | LONZA AG (CH) | 1996-10-17 | — | — | WO | disclosed |
| US-4067741-A | Hardening photographic layers containing silver halide with a 1-sulphonyl-4-amino-pyridinium salt | AGFA-GEVAERT, A.G. (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | COL2A1, FN1, TNNC1 | NOS3 3193/4885NOS1 3146/4885NOS2 2434/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | NOS3 578/4885NOS1 471/4885NOS2 558/4885 |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | NOS3 2061/4885NOS1 1981/4885NOS2 1657/4885 |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ILK, PLOD3, MMP1 | NOS3 463/4885NOS1 529/4885NOS2 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.